These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 15882669

  • 1. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 25; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 3. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Acta Cardiol; 2003 Jun 25; 58(3):179-84. PubMed ID: 12846506
    [Abstract] [Full Text] [Related]

  • 4. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 25; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 25; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 25; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 7. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, LIPID Study Investigators.
    Eur Heart J; 2004 May 25; 25(9):771-7. PubMed ID: 15120888
    [Abstract] [Full Text] [Related]

  • 8. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP.
    Curr Med Res Opin; 2007 Sep 25; 23(9):2183-92. PubMed ID: 17692154
    [Abstract] [Full Text] [Related]

  • 9. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 25; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 25; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 25; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 25; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 13. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS, Mikhailidis DP.
    Curr Med Res Opin; 2006 Mar 25; 22(3):511-28. PubMed ID: 16574035
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 25; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 15. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC, Otto C, Parhofer KG.
    Metabolism; 2006 May 25; 55(5):599-604. PubMed ID: 16631435
    [Abstract] [Full Text] [Related]

  • 16. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 25; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 18. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun 10; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 19. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.
    Clin Ther; 2006 Feb 10; 28(2):243-50. PubMed ID: 16678645
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.